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Infective endocarditis (IE) is a life-threatening disease associated with serious complications. The GBD 2010
(Global Burden of Disease, Injuries, and Risk Factors) study IE expert group conducted a systematic review of
IE epidemiology literature to inform estimates of the burden on IE in 21 world regions in 1990 and 2010.
The disease model of IE for the GBD 2010 study included IE death and 2 sequelae: stroke and valve surgery.
Several medical and science databases were searched for IE epidemiology studies in GBD high-, low-, and
middle-income regions published between 1980 and 2008. The epidemiologic parameters of interest were IE
incidence, proportions of IE patients who developed stroke or underwent valve surgery, and case fatality.
Literature searches yielded 1,975 unique papers, of which 115 published in 10 languages were included in
the systematic review. Eligible studies were population-based (17%), multicenter hospital-based (11%), and
single-center hospital-based studies (71%). Population-based studies were reported from only 6 world
regions. Data were missing or sparse in many low- and middle-income regions. The crude incidence of IE
ranged between 1.5 and 11.6 cases per 100,000 people and was reported from 10 countries. The overall
mean proportion of IE patients that developed stroke was 0.158  0.091, and the mean proportion of
patients that underwent valve surgery was 0.324  0.188. The mean case fatality risk was 0.211  0.104.
A systematic review for the GBD 2010 study provided IE epidemiology estimates for many world regions, but
highlighted the lack of information about IE in low- and middle-income regions. More complete knowledge
of the global burden of IE will require improved IE surveillance in all world regions.Center, Durham, NC, USA;
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CC BY-NC-ND license.Infective endocarditis (IE) is a serious life-threatening
disease, with up to 22% in-hospital and 40% 5-year mortal-
ity rates [1e3]. IE is also associated with signiﬁcant compli-
cations among survivors, including heart failure, usually
because of severe valvular insufﬁciency, and embolic stroke.
Valve surgerymaybe life-saving and has been shown to reduce
embolic risk [4]. Themagnitude of global health loss due to IE
is largely unknown as it was not speciﬁcally included in the
previous iterations of the GBD (Global Burden of Disease, In-
juries, and Risk Factors) study [5,6]. A previous report indi-
cateda scarcity of representative IE epidemiologic surveys from
many countries [7]. Furthermore, no comprehensive assess-
ments of the incidence, mortality, burden, and sequelae of IE
have been undertaken previously for most areas of the world.
The GBD study is a systematic, scientiﬁc effort to quantify
the comparative magnitude of health loss due to diseases,
injuries, and risk factors by age, sex, and geography for spe-
ciﬁc points in time [8]. The GBD studywas initiated byWorld
Bank in 1991 and used standard methods to provide a
comprehensive assessment of the mortality and disability
burden ofmajor diseases, injuries, and risk factors for the year
1990 [5,6,9]. However, IE was not included among major
diseases in the 1990 study. The GBD 2010 study aimed toGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 131-143improve and update GBDmethods and analyze the burden of
diseases, risk factors, and injuries for the years 1990, 2005,
and 2010 in 21world regions for 291 diseases and risk factors
and 1,161 sequelae among 20 age groups for each sex sepa-
rately [8]. The GBD 2010 study’s hierarchical causes list
included IE among the 291 diseases.
Here, we summarize the methodology of the compre-
hensive systematic review used to estimate the global burden
of IE and provide summary data about the crude incidence
and sequelae of IE.METHODS
GBD 2010 study deﬁnitions related to infective
endocarditis
IE was deﬁned by any of the following criteria: Pelletier and
Petersdorf [10], Von Reyn or modiﬁed Von Reyn [11], Duke
or modiﬁed Duke [12,13] criteria. A simpliﬁed disease model
for the systematic review of IE was employed (Fig. 1). Stroke
was deﬁned as a neurological deﬁcit that lasts >24 h and of
presumed vascular origin [14]. Valve surgery included either
valve replacement or repair.j.gheart.2014.01.002
131
FIGURE 1. Infective endocarditis disease model. Simpli-
ﬁed disease model for systematic review.
j gREVIEW
132The GBD 2010 study divided the world into 21 world
regions on the basis of epidemiology, homogeneity, and
geographical contiguity (Fig. 2).
Search strategy
Ovid Medline, Ovid Embase, Global Health Library,
AMED (Allied and Complementary Medicine Database),
EXTRAMed, Scopus, Web of Science, SciELO (Scientiﬁc
Electronic Library Online), and the Ovid Cochrane databasesFIGURE 2. The 21 world regions of Global Burden owere searched for relevant publications dating from January 1,
1980 through December 31, 2008. The search strategies
used both subject headings and text words for the epidemi-
ology of IE, such as “endocarditis,” “bacterial/epidemiology,”
“ethnology,” and “mortality,” as well as text words “bacterial
endocarditis,” “infectious/infective endocarditis,” and “epide-
miologic,” “ethnic,” “incidence,” and “prevalence.” The strat-
egy was tailored to each database to allow for the variations in
structure and terminology. Bibliographies of full-text papers
identiﬁed in the electronic search were also manually
reviewed for additional eligible studies. All results were
downloaded into EndNote 7.0 (Thompson ISI Research Soft,
Philadelphia, PA, USA), a bibliographic database manager,
and duplicate citations were identiﬁed and removed.
Study selection
Any study that reported an incidence or sequelae of IE was
eligible for inclusion. Population-based studies would only
be considered if they included 4 methodological compo-
nents (deﬁned general population, use of IE diagnostic
criteria, adequate sampling techniques, and case ascertain-
ment) [7]. There were no language or age restrictions. Non-
English language studies were translated by a group of heath
researchers/translators assigned by the GBD 2010 study.f Disease, Risk Factors, and Injuries 2010 study.
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FIGURE 3. Flow diagram of the included studies.
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Data extraction
Two reviewers (A.B. and I.T.) independently extracted data
into a pre-designed data collection form. Final study in-
clusion was only considered if both reviewers were in
agreement and any inconsistency was discussed with IE
expert group. Data was extracted from selected studies
regarding the study’s deﬁnition of IE, sampling method,
case ﬁnding procedures, country of origin, type of the
study (population-based, multicenter hospital-based, and
single-center hospital-based), study period, method of
calculating estimates, size and age and sex composition of
the sample, incidence of IE, frequency of valve surgeries,
incidence of stroke, mortality deﬁnitions, and short- and
long-term mortality among IE patients.
Statistical analysis
Summary estimates of the incidence of stroke or valve
surgery and case fatality risk estimated from the systematic
review study data are presented as mean  SD and median
(interquartile range [IQR]), respectively. The crude inci-
dence was reported as number of patients per 100,000
people. Incidence of stroke and valve surgeries and case
fatality risks among IE patients were stratiﬁed on type of
patient cohorts for comparison. Evidence of differences in
rates by study type were tested using the Kruskal-Wallis
test and a p value of <0.05 was indicative of a signiﬁ-
cant difference.
RESULTS
Yield of search strategy
The initial search strategy yielded 1,975 publications, and
1,860 studies were excluded after careful review of full-text
publications. One hundred ﬁfteen citations [15e129] were
included that were published in 10 languages. Tleyjeh et al.
[117] reported on 4 different periods and thus accounted
for 4 results from this 1 study. Figure 3 summarizes the
results of the systematic review.
Descriptive overview of the included studies
Of 115 eligible studies, 20 (17%) were population-based, 13
(11%) were multicenter hospital-based, and 82 (71%) were
single-center hospital-based studies. Population-based
studies were reported from only 6 (29%) of 21 world re-
gions (High Income North America, Western Europe,
Eastern Europe, North Africa/Middle East, Australasia, and
Southern Latin America) and multicenter studies from 5
(24%) of the world regions (Western Europe, Eastern
Europe, High Income Asian Paciﬁc, North Africa/Middle
East, Southern Latin America). Duke criteria was used in 8 of
the population-based studies followed by modiﬁed Duke
(4 studies) and Von Reyn (4 studies) andmodiﬁed Von Reyn
(3 studies). Eligible studies covered only 16 (76%) of the
world regions; no studies were found from Central Asia, the
Caribbean, Andean Latin America, Oceania, or Eastern Sub-
Saharan Africa. The included studies reported data on bothGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 131-143sexes with a wide range of ages from 0 to 106 years. Table 1
summarizes general characteristics of the included studies.
The incidence and outcomes reported in the included
studies are summarized in Table 2.
Crude incidence of IE
IE incidence was reported in 17 of 20 population-based
studies from only 4 world regions (High Income North
America, Western Europe, North Africa/Middle East,
Australasia). These broad geographic regions were repre-
sented by only 10 countries: Australia, Denmark, France,
Greece, Italy, the Netherlands, Sweden, Tunisia, the United
States, and the United Kingdom. In these studies, the crude
incidence of IE was in the range of 1.5 to 11.6 cases per
100,000 people. The highest incidence was reported from
the United States (11.6 cases per 100,000 people) and
the lowest from the Netherlands (1.5. cases per 100,000
people). However, IE incidence varied greatly, including
within the same country (Fig. 4).
Sequelae of IE
Stroke. The overall mean proportion of IE patients who
developed stroke reported from all studies was 0.158 
0.091; the median was 0.136 (IQR: 0.099). The median
proportions of IE patients that developed stroke from133
TABLE 1. Characteristics of included studies
Reference First Author Sex
Country
Code Country Geographic Region
Minimum
Age, yrs
Maximum
Age, yrs
Study
Starting
Year
Study
Ending
Year Study Type
15 Ako J Both JPN Japan Asia Paciﬁc, High
Income
6 82 1980 1999 Hospital cohort
16 Aksoy O Both USA United States North America, High
Income
6 11 1996 2002 Hospital cohort
17 Alshammary A Both CAN Canada North America, High
Income
0 16 1985 2004 Hospital cohort
18 Anavekar NS Both USA United States North America, High
Income
18 100 1980 1998 Hospital cohort
19 Arzanauskiene R Both LTU Lithuania Europe, Eastern 18 82 1999 2001 Hospital cohort
20 Ashkenazi S Both ISR Israel North Africa/Middle
East
0 16 1980 1991 Hospital cohort
21 Assef MA Both BRA Brazil Latin America, Tropical 2 76 1980 1987 Hospital cohort
22 Ben HK Both TUN Tunisia North Africa/Middle
East
5 67 1982 2000 Hospital cohort
23 Ben-Ami R Both ISR Israel North Africa/Middle
East
38 104 1995 1998 Hospital cohort
24 Benn M Both DNK Denmark Europe, Western 14 84 1984 1993 Population
25 Bennis A Both MAR Morocco North Africa/Middle
East
11 65 1983 1994 Hospital cohort
26 Berkowitz FE Both ZFA South Africa Sub-Saharan Africa,
Southern
0 9 1986 1988 Hospital cohort
27 Berlin JA Both USA United States North America, High
Income
18 100 1988 1990 Population
28 Bhat AW Both IND India Asia, South 0 15 1983 1993 Hospital cohort
29 Bishara J Both ISR Israel North Africa/Middle
East
18 93 1987 1996 Hospital cohort
30 Blackett K Both CMR Cameroon Sub-Saharan Africa,
West
8 70 1984 1980 Hospital cohort
31 Blumberg EA Both USA United States North America, High
Income
14 81 1985 1990 Hospital cohort
32 Borer A Both ISR Israel North Africa/Middle
East
16 84 1980 1994 Hospital cohort
33 Bouza E Both ESP Spain Europe, Western 19 89 1994 1996 Hospital cohort
34 Braun S Both CHL Chile Latin America, Southern 0 100 1980 1999 Hospital cohort
35 Buchholtz K Both DNK Denmark Europe, Western 31 91 2002 2003 Multicenter
36 Carceller A Both CAN Canada North America, High
Income
0 18 1986 2000 Hospital cohort
37 Cecchi E Both ITA Italy Europe, Western 15 89 2000 2001 Multicenter
38 Chao TH Both TWN Taiwan Asia, East 17 100 1990 1997 Hospital cohort
39 Cheng A Both AUS Australia Australasia 20 94 1994 1999 Population
40 Choudhury R Both IND India Asia, South 2 75 1981 1991 Hospital cohort
41 Chu J Both NZL New Zealand Australasia 7 89 1997 2002 Hospital cohort
42 Chu VH Both USA United States North America, High
Income
26 90 1996 2001 Hospital cohort
43 Cicalini S Both ITA Italy Europe, Western 9 68 1980 2003 Hospital cohort
44 Costa MA Both BRA Brazil Latin America, Tropical 7 70 1988 1998 Hospital cohort
45 Coward K Both USA United States North America, High
Income
0 28 1990 2002 Hospital cohort
46 Delahaye F Both FRA France Europe, Western 0 91 1990 1991 Population
47 Dhawan A Both IND India Asia, South 2 16 1984 1990 Hospital cohort
48 Di Salvo G Both ITA/FRA Italy/France Europe, Western 17 88 1993 2002 Multicenter
49 Dyson C Both GBR United Kingdom Europe, Western 0 89 1987 1996 Hospital cohort
50 Ejima K Both JPN Japan Asia Paciﬁc, High
Income
0 85 1984 2003 Hospital cohort
51 Fedorova TA Both RUS Russian Federation Europe, Eastern 16 81 2000 2007 Hospital cohort
52 Ferreiros E Both ARG Argentina Latin America, Southern 24 93 2002 2002 Multicenter
53 Foghsgaard J Both DNK Denmark Europe, Western 0 100 1990 2000 Population
54 Fonager K Both DNK Denmark Europe, Western 15 100 1980 97 Population
55 Garg N Both IND India Asia, South 4 68 1992 2001 Hospital cohort
56 Giannitsioti E Both GRC Greece Europe, Western 53 73 2000 2004 Population
57 Gotsman I Both ISR Israel North Africa/Middle
East
1 97 1991 2000 Hospital cohort
58 Goulet V Both FRA France Europe, Western 1 89 1982 1983 Population
(continued)
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TABLE 1. Continued
Reference First Author Sex
Country
Code Country Geographic Region
Minimum
Age, yrs
Maximum
Age, yrs
Study
Starting
Year
Study
Ending
Year Study Type
59 Heiro M Both FIN Finland Europe, Western 20 89 1980 2004 Hospital cohort
60 Hermida Ameijeinas A Both ESP Spain Europe, Western 19 84 1989 2003 Hospital cohort
61 Hill EE Both BEL Belgium Europe, Western 54 73 2000 2004 Hospital cohort
62 Hoen B Both FRA France Europe, Western 16 95 1999 1999 Population
63 Hogevik H Both SWE Sweden Europe, Western 8 88 1984 1988 Population
64 Hricak V Both SVK Slovakia (Slovak
Republic)
Europe, Eastern 0 100 1984 2006 Multicenter
65 Hsu CN Both TWN Taiwan Asia, East 0 92 1995 2003 Hospital cohort
66 Hwang JJ Both TWN Taiwan Asia, East 14 75 1989 1991 Hospital cohort
67 Hwang JJ Both TWN Taiwan Asia, East 17 75 1989 1992 Hospital cohort
68 Ifere OA Both NGA Nigeria Sub-Saharan Africa,
West
0 15 1982 1989 Hospital cohort
69 Jaffe WM Both USA United States North America, High
Income
15 88 1983 1988 Hospital cohort
70 Jain V Both USA United States North America, High
Income
18 100 1993 2003 Hospital cohort
71 Janion M Both POL Poland Europe, Central 0 100 2001 2005 Hospital cohort
72 Jorge Sdo C Both BRA Brazil Latin America, Tropical 0 76 1985 1990 Hospital cohort
73 Jung HO Both KOR Korea, Republic of
(South Korea)
Asia Paciﬁc, High
Income
11 73 1983 1993 Multicenter
74 Kanafani ZA Both LBN Lebanon North Africa/Middle
East
13 87 1986 2001 Hospital cohort
75 King J Both USA United States North America, High
Income
15 90 1985 1986 Population
76 Knyshov GV Both UKR Ukraine Europe, Eastern 1 75 1982 200 Hospital cohort
77 Koegelenberg CF Both ZAF South Africa Sub-Saharan Africa,
Southern
7 69 1997 2000 Hospital cohort
78 Krcmery V NA SVK Slovakia (Slovak
Republic)
Europe, Eastern NA NA 1991 2001 Population
79 Leblebicioglu H Both TUR Turkey North Africa/Middle
East
18 100 2002 2004 Multicenter
80 Letaief A Both TUN Tunisia North Africa/Middle
East
0 66 1991 2000 Population
81 Lewena S Both AUS Australia Australasia 0 17 1985 2001 Hospital cohort
82 López-Dupla M Both ESP Spain Europe, Western 15 86 1990 2004 Hospital cohort
83 Loupa C Both GRC Greece Europe, Western 17 86 1997 2000 Multicenter
84 Manford M Both GBR United Kingdom Europe, Western 23 85 1983 1989 Incidence
85 Milovsky V Both SVK Slovakia (Slovak
Republic)
Europe, Eastern 3 18 1990 1997 Multicenter
86 Mouly S Both FRA France Europe, Western 23 90 1997 1998 Hospital cohort
87 Moura L Both ESP Spain Europe, Western 26 86 1989 2001 Hospital cohort
88 Mourvillier B Both FRA France Europe, Western 18 84 1993 2000 Hospital cohort
89 Nadji G Both FRA France Europe, Western 30 90 1990 2003 Hospital cohort
90 Nashmi A Both SAU Saudi Arabia North Africa/Middle
East
0 78 1993 2003 Hospital cohort
91 Netzer ROM Both CHE Switzerland Europe, Eastern 17 90 1980 1995 Hospital cohort
92 Nkoua JL Both COR Congo, Republic of
(Brazzaville)
Sub-Saharan Africa,
Central
1 53 1985 1990 Hospital cohort
93 Nolsøe C Both DNK Denmark Europe, Western 0 100 1981 1983 Population
94 Expósito Ordóñez E Both ESP Spain Europe, Western 11 86 1992 1996 Hospital cohort
95 Ostrowski S Both POL Poland Europe, Central 19 70 1986 1994 Hospital cohort
96 Oyonarte M Both CHE Chile Latin America, Southern 12 86 1998 2002 Population
97 Pachirat O Both THA Thailand Asia, Southeast 15 75 1990 1999 Hospital cohort
98 Pachirat O Both THA Thailand Asia, Southeast 4 74 1990 2002 Hospital cohort
99 Paganini H Both ARG Argentina Latin America, Southern 2 14 1988 2000 Hospital cohort
100 Pedersen SA Both DNK Denmark Europe, Western 0 100 1990 2000 Population
101 Pereira CA Female BRA Brazil Latin America, Tropical 0 13 1993 2001 Hospital cohort
102 Pergola V Both FRA France Europe, Western 27 87 1993 2001 Hospital cohort
103 Roca B Both ESP Spain Europe, Western 22 84 1999 2004 Hospital cohort
104 Rozwodowska M Both POL Poland Europe, Central 18 78 1998 2000 Hospital cohort
105 Ruiz Júnior E Both BRA Brazil Latin America, Tropical 0 106 1992 1997 Hospital cohort
106 Sadiq M Both PAK Pakistan Asia, South 0 16 1997 2000 Hospital cohort
(continued)
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TABLE 1. Continued
Reference First Author Sex
Country
Code Country Geographic Region
Minimum
Age, yrs
Maximum
Age, yrs
Study
Starting
Year
Study
Ending
Year Study Type
107 Sekido M Both JPN Japan Asia Paciﬁc, High
Income
18 68 1986 1996 Hospital cohort
108 Skehan JD Both GBR United Kingdom Europe, Western 19 91 1982 1984 Population
109 Smith JM Both USA United States North America, High
Income
18 100 1993 2004 Hospital cohort
110 Souto Meiriño CA Both MEX Mexico Latin America, Central 0 100 1990 1994 Hospital cohort
111 Tariq M Both PAK Pakistan Asia, South 0 72 1997 2001 Hospital cohort
112 Teixeira F Both PRT Portugal Europe, Western 1 15 1993 1997 Hospital cohort
113 Thalme A Both SWE Sweden Europe, Western 40 72 1995 2000 Hospital cohort
114 Thuny F Both FRA France Europe, Western 17 96 1990 2005 Multicenter
115 Thuny F Both FRA/ITA France/Italy Europe, Western 16 94 1993 2003 Multicenter
116 Tiurin VP Both RUS Russian Federation Europe, Eastern 17 78 1980 1996 Hospital cohort
117 Tleyjeh IM Both USA United States North America, High
Income
34 89 1995 2000 Population
117 Tleyjeh IM Both USA United States North America, High
Income
28 84 1990 1994 Population
117 Tleyjeh IM Both USA United States North America, High
Income
24 81 1985 1989 Population
117 Tleyjeh IM Both USA United States North America, High
Income
19 90 1980 1984 Population
118 Tornos P Both Europe (international) Europe 25 89 2001 2001 Multicenter
119 Tran CT Both DNK Denmark Europe, Western 19 83 1998 2000 Hospital cohort
120 Van der Meer JT Both NLD Netherlands Europe, Western 2 89 1986 1988 Population
121 Venkatesan C Both USA United States North America, High
Income
0 16 1990 2007 Hospital cohort
122 Vlessis AA Both USA United States North America, High
Income
11 90 1982 1992 Hospital cohort
123 Wallace SM Both GBR United Kingdom Europe, Western 0 100 1981 1999 Hospital cohort
124 Walpot J Both NLD Netherlands Europe, Western 36 81 2002 2004 Population
125 Werner M Both SWE Sweden Europe, Western 14 100 1995 2005 Multicenter
126 Zacherl S Both AUS Australia Australasia 0 18 1983 1993 Hospital cohort
127 Zaliaduonyte-Peksiene
D
Both LTU Lithuania Europe, Eastern 24 85 2002 2005 Hospital cohort
128 Zamorano J Both ESP Spain Europe, Western 0 100 1991 1991 Hospital cohort
129 Zarzur J Both MAR Morocco North Africa/Middle
East
0 100 1995 2001 Hospital cohort
NA, not available.
j gREVIEW
136population-based, multicenter hospital-based, and single-
center hospital-based studies were 0.152 (IQR: 0.039),
0.145 (IQR: 0.069), and 0.122 (IQR: 0.119), respectively.
Southern Latin America recorded the highest stroke
proportion (0.19) followed by North Africa/Middle East
(0.18), Eastern Europe (0.166), Sub-Saharan Africa
Southern (0.166), South Asia (0.160), Western Europe
(0.143), Tropical Latin America (0.138), North America
(0.123), Southern Asia (0.118), Australia (0.087), Central
Europe (0.083), and East Asia (0.066). No data about
stroke were available for other world regions.
Valve surgery. The overall mean proportion of IE patients
that underwent valve surgery was 0.324  0.188, whereas
the median was 0.267 (IQR: 0.286). The median pro-
portions of IE patients that underwent valve surgery from
population-based, multicenter hospital-based, and single-
center hospital-based studies were 0.229 (IQR: 0.138),
0.523 (IQR: 0.00), and 0.277 (IQR: 0.286), respectively.
Eastern Europe has the highest proportion of valve
surgeries (0.75) followed by Southeast Asia (0.47), AsiaPaciﬁc (0.46), Latin America (0.413), Central Europe
(0.410), Latin America (0.39), Southern Sub-Saharan Af-
rica (0.383), North Africa/Middle East (0.380), Western
Europe (0.37), North America (0.31), East Asia (0.28),
Australia (0.24), and South Asia (0.124).
Overall mortality. Mortality information was reported
from only 8 world regions. No mortality time element was
reported from a majority of the studies. Southern Latin
America followed by Eastern Europe and then East Asia
have reported the highest case fatality risk from IE with a
mean overall risk from all included studies of 0.211 
0.104, and the median was 0.200 (IQR: 0.126). The me-
dian case fatality risks from population-based, multicenter
hospital-based, and single-center hospital-based studies
were 0.200 (IQR: 0.112), 0.150 (IQR: 0.127), and 0.200
(IQR: 0.132), respectively.
Comparison of sequelae risks by study design. There
were no statistically signiﬁcant differences in theGLOBAL HEART, VOL. 9, NO. 1, 2014
March 2014: 131-143
TABLE 2. Outcomes of included studies
Reference Principle Author
Incidence
per 100,000
People
Valve
Surgery
Proportion
Stroke
Proportion
Mortality
Proportion
Sample
Size
15 Ako J NR 0.659 NR 0.154 194
16 Aksoy O NR 0.286 0.173 0.169 426
17 Alshammary A NR 0.2 NR 0.05 40
18 Anavekar NS NR NR 0.116 0.471 600
19 Arzanauskiene R NR NR NR 0.246 138
20 Ashkenazi S NR NR NR 0.04 25
21 Assef MA NR NR NR 0.397 83
22 Ben HK NR 0.547 0.293 0.301 126
23 Ben-Ami R NR NR NR 0.241 87
24 Benn M 2.7 0.322 0.435 0.354 62
25 Bennis A NR 0.101 0.101 0.286 157
26 Berkowitz FE NR 0.2 0.4 0.6 10
27 Berlin JA NR NR NR NR 670
28 Bhat AW NR 0 NR 0.25 28
29 Bishara J NR 0.173 NR 0.272 213
30 Blackett K NR 0.25 NR 0.35 20
31 Blumberg EA NR NR NR 0.254 51
32 Borer A NR 0.154 0.084 0.169 71
33 Bouza E NR 0.229 0.119 0.256 109
34 Braun S NR 0.523 0.192 0.16 261
35 Buchholtz K NR 0.545 NR 0.138 231
36 Carceller A NR 0.107 0.196 0.125 56
37 Cecchi E 3.6 0.306 0.136 0.19 147
38 Chao TH NR 0.284 NR 0.25 88
39 Cheng A 3 0.31 NR 0.172 58
40 Choudhury R NR 0.005 0.163 0.247 190
41 Chu J NR 0.184 0.076 0.2 65
42 Chu VH NR 0.265 0.202 0.187 267
43 Cicalini S 0.116 0.109 0.14 283
44 Costa MA NR 0.639 NR 0.263 186
45 Coward K NR 0.298 NR 0.122 57
46 Delahaye F 2.2 0.244 0.036 0.21 415
47 Dhawan A NR NR 0.135 0.432 37
48 Di Salvo G NR 0.482 0.139 0.107 315
49 Dyson C NR NR NR 0.172 122
50 Ejima K NR 0.266 NR 0.266 75
51 Fedorova TA NR NR 0.258 0.258 112
52 Ferreiros E NR 0.261 0.205 0.246 390
53 Foghsgaard J 3.5 NR NR NR 135
54 Fonager K 3.7 F
5.1 M
NR NR 0.234 3,351
55 Garg N NR 0.164 0.121 0.21 198
56 Giannitsioti E 2.1 0.271 NR 0.2 195
57 Gotsman I NR 0.25 NR 0.08 100
58 Goulet V 1.8 0.28 NR 0.211 288
59 Heiro M NR 0.279 0.101 0.131 326
60 Hermida Ameijeinas A NR 0.252 0.045 0.08 87
61 Hill EE NR 0.632 0.227 0.217 193
62 Hoen B 3 0.489 0.164 0.158 390
63 Hogevik H 6.2 0.151 0.121 0.131 99
(continued)
gREVIEWj
GLOBAL HEART, VOL. 9, NO. 1, 2014 137
March 2014: 131-143
TABLE 2. Continued
Reference Principle Author
Incidence
per 100,000
People
Valve
Surgery
Proportion
Stroke
Proportion
Mortality
Proportion
Sample
Size
64 Hricak V NR 0.425 NR 0.15 606
65 Hsu CN NR NR 0.066 0.215 315
66 Hwang JJ NR 0.325 NR 0.093 43
67 Hwang JJ NR 0.5 0.08 0.12 50
68 Ifere OA NR NR 0.151 0.4848 33
69 Jaffe WM NR 0.514 0.271 0.1 70
70 Jain V NR NR 0.06 0.149 247
71 Janion M NR 0.543 NR 0.122 57
72 Jorge Sdo C NR 0.326 NR 0.231 263
73 Jung HO NR NR 0.325 0.262 80
74 Kanafani ZA NR 0.241 0.12 0.175 91
75 King J 1.7 0.333 0.1333 0.12 75
76 Knyshov GV NR 0.754 NR NR 1,128
77 Koegelenberg CF NR 0.383 0.166 0.283 60
78 Krcmery V NR
79 Leblebicioglu H NR 0.133 NR 0.285 112
80 Letaief A 5.5 0.506 0.163 0.204 440
81 Lewena S NR 0.304 0.26 0.086 23
82 López-Dupla M NR 0.2 NR 0.191 120
83 Loupa C NR 0.445 NR 0.158 101
84 Manford M NR 0.333 0.151 0.242 33
85 Milovsky V NR 0.3 NR 0.2 20
86 Mouly S NR 0.555 0.2 0.2 90
87 Moura L NR 0.413 NR NR 150
88 Mourvillier B NR 0.456 0.298 0.447 228
89 Nadji G NR 0.377 NR 0.248 310
90 Nashmi A NR 0.446 0.234 0.085 47
91 Netzer ROM NR 0.382 NR 0.24 212
92 Nkoua JL NR 0.487 NR 0.512 39
93 Nolsøe C 1.8 NR NR NR 33
94 Expósito Ordóñez E NR 0.223 0.035 0.094 85
95 Ostrowski S NR 0.95 NR 0.191 120
96 Oyonarte M NR 0.352 NR 0.271 321
97 Pachirat O NR 0.45 0.118 0.25 160
98 Pachirat O NR 0.49 NR 0.225 200
99 Paganini H NR 0.244 0.197 0.127 86
100 Pedersen SA NR 0.422 NR 0.14 135
101 Pereira CA NR NR NR 0.035 28
102 Pergola V NR 0.577 0.169 0.092 206
102 Roca B NR 0.092 NR 0.27 54
104 Rozwodowska M NR 0.25 0.083 0.196 56
105 Ruiz Júnior E NR 0.211 0.138 0.405 180
106 Sadiq M NR 0.088 0.066 0.133 45
107 Sekido M NR 0.605 0.078 0.157 38
108 Skehan JD 2.3 0.183 NR 0.21 185
109 Smith JM NR 0.505 NR 0.114 87
110 Souto Meiriño CA NR NR NR 0.274 131
111 Tariq M NR 0.09 0.212 0.272 66
112 Teixeira F NR 0.428 NR 0.142 7
113 Thalme A NR 0.187 NR 0.088 192
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TABLE 2. Continued
Reference Principle Author
Incidence
per 100,000
People
Valve
Surgery
Proportion
Stroke
Proportion
Mortality
Proportion
Sample
Size
114 Thuny F NR 0.596 0.125 0.118 496
115 Thuny F NR 0.523 0.161 0.205 384
116 Tiurin VP NR NR 0.406 NR 172
117 Tleyjeh IM 6.3 0.148 NR 0.296 27
117 Tleyjeh IM 6.5 0.095 NR 0.333 21
117 Tleyjeh IM 7 0.2 NR 0.2 20
117 Tleyjeh IM 5 0.214 NR 0.142 14
118 Tornos P NR 0.484 0.15 0.125 159
119 Tran CT NR 0.386 NR 0.147 163
120 Van der Meer JT 1.5 NR NR 0.197 438
121 Venkatesan C NR NR 0.06 NR 115
122 Vlessis AA NR 0.407 0.042 0.371 140
123 Wallace SM NR 0.514 0.1 0.269 208
124 Walpot J 9.6 0.37 0.125 0.343 32
125 Werner M NR 0.202 NR 0.106 2,509
126 Zacherl S NR 0.312 NR 0.062 16
127 Zaliaduonyte-Peksiene D NR NR 0.043 NR 116
128 Zamorano J NR 0.495 NR 0.135 103
129 Zarzur J NR NR 0.121 NR 82
F, female; M, male; NR, not reported.
FIGURE 4. Incidence of infective endocarditis among different countries.
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TABLE 3. Comparison of infective endocarditis sequelae among study designs
Variable Single-Center Hospital-Based Multicenter Hospital-Based Population-Based
Signiﬁcance,
Kruskal-Wallis Test
Median valve surgery 0.277 (0.286) 0.523 (0.00) 0.229 (0.138) X2 ¼ 3.411,
p ¼ 0.1817
Median stroke 0.122 (0.119) 0.145 (0.069) 0.152 (0.039) X2 ¼ 1.554,
p ¼ 0.4599
Median mortality 0.200 (0.132) 0.150 (0.127) 0.200 (0.112) X2 ¼ 2.123,
p ¼ 0.3460
Values are proportions (interquartile ranges).
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and mortality) among different types of study designs
(Table 3).DISCUSSION
A comprehensive systematic review of the literature in 21
world regions revealed that IE, though an uncommon
disease in the general population, is associated with sig-
niﬁcant morbidity and mortality. Additionally, the majority
of the epidemiological ﬁndings are primarily from single
hospital-based cohorts, with no data reported from Central
Asia, Caribbean, Andean Latin America, Oceania, and
Eastern Sub-Saharan Africa regions that constitute 24% (5
of 21) of the world’s regions.
Ideally, the epidemiology of IE should be derived from
population-based studies, due to the inﬂuence of a well-
recognized referral bias on the observed proﬁle of IE
[130]. However, population-based studies represent only
17% of the current literature of IE, representing only 6
world regions, and even these regions were represented by
studies of only 10 countries. Nevertheless, no statistically
signiﬁcant differences were observed among IE sequelae
incidence among population-based studies, multicenter
hospital-based studies, and single-center hospital-based
cohorts. However, sampling from different populations,
and referral bias may explain the absence of difference in
the sequelae incidence among different study designs.
Nonetheless, multicenter or single-center hospital-based
cohorts could be used to estimate the global burden of IE
in areas of the world that have not been characterized by
population-based studies.
Based on these limited data, IE incidence appears to be
generally low. IE incidence appears to vary greatly among
different populations even within the same country. In the
United States, for example, the incidence varied from 1.7 to
11.6 cases per 100,000 people. Multiple factors could have
led to variability in IE incidence, including referral and case
ascertainment biases, disease misclassiﬁcation, differences
in populations at risk, study designs, and use of different
case deﬁnitions [7]. Moreover, IE can be associated with
devastating outcomes. Almost 1 in 4 cases of IE will not
survive.Although our review was very comprehensive and
aimed to globally estimate the IE burden, there are certain
challenges that include incompleteness and nonrepresen-
tative biases, missing data from several countries, inability
to access unpublished data, and effect of referral bias that
make our goals difﬁcult.
Despite searching multiple library databases and the
inclusion of studies published in several languages, few IE
epidemiology studies were identiﬁed in our systematic
review. Incidence of IE is largely unknown in most parts of
the world due to scarcity of population-based studies from
several world regions. Efforts should be made to report the
incidence of IE using a standard case deﬁnition and to
assist health planners and policy makers with setting the
appropriate strategies to decrease the burden of this often
fatal or disabling disease.SUMMARY
Our study represents the ﬁrst comprehensive effort to esti-
mate the global burden of IE in 21 world regions for the
years 1990 and 2010. IE literature covered 76% of the world
regions, and it primarily included hospital-based cohorts
with substantially fewer population-based studies. Although
IE is an uncommon disease, it is associated with signiﬁcant
morbidity and mortality. High-quality population-based
studies are urgently needed and may permit a better estimate
of the global burden of IE.REFERENCES
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